[{"Assets_0_Q2_USD":4624679000.0,"CommonStockSharesConverted_0_Q2_shares":177508135.0,"CommonStockSharesOutstanding_0_Q2_shares":177508135.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-76366000.0,"NetIncomeLossConverted_1_Q2_USD":-16792000.0,"NetIncomeLossConverted_2_Q2_USD":-60941000.0,"StockholdersEquity_0_Q2_USD":2885104000.0,"EarningsPerShareBasic_1_Q2_USD":-0.09,"EarningsPerShareBasic_2_Q2_USD":-0.35,"RevenuesConverted_1_Q2_USD":372845000.0,"RevenuesConverted_2_Q2_USD":746292000.0,"Ticker":"BMRN","CIK":"1048477","name":"BIOMARIN PHARMACEUTICAL INC","OfficialName":"BioMarin Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"14899091235.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180803"}]